Retno Hesty Maharani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Retno Hesty Maharani has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Pati Aji Achdiat
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
17 shared publications - Hermin Aminah Usman
Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, Indonesia
7 shared publications - Eva Krishna Sutedja
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
5 shared publications - Laila Tsaqilah
Department of Dermatology Venereology and Aesthetics, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
5 shared publications Rasmia Rowawi
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
5 shared publications- Risa Miliawati Nurul Hidayah
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
5 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-6
Anogenital Warts in an Elderly Male: Clinical and Public Health Perspectives
Anogenital warts (AGWS), caused by human papillomavirus (HPV), are among the most common sexually transmitted infections (STIs). Although AGWS is more commonly found in younger adults, cases in older individuals are increasingly being reported. A 76-year-old man presented with progressively enlarging brown papules in the genital area (penile base, scrotum, and left inguinal fold). Histopathological examination showed epidermal hyperplasia, papillomatosis, acanthosis, and koilocytosis. PCR examination confirmed low-risk HPV types 6 and 11. The patient reported a history of multiple sexual partners, did not use condoms during sexual intercourse, and had limited knowledge regarding STIs transmission based on a questionnaire. The patient was treated with cryotherapy and lesion excision. At the final observation, complete lesion resolution was achieved with no new lesions observed. In conclusion, this case highlights the importance of maintaining clinical awareness of AGWs in older adults. Thorough diagnostic evaluation, sexual health education, regular STIs screening, and counseling should be integrated into routine care for the elderly population.
- 1 November 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-6
Open AccessAnogenital Warts in an Elderly Male: Clinical and Public Health Perspectives
Anogenital warts (AGWS), caused by human papillomavirus (HPV), are among the most common sexually transmitted infections (STIs). Although AGWS is more commonly found in younger adults, cases in older individuals are increasingly being reported. A 76-year-old man presented with progressively enlarging brown papules in the genital area (penile base, scrotum, and left inguinal fold). Histopathological examination showed epidermal hyperplasia, papillomatosis, acanthosis, and koilocytosis. PCR examination confirmed low-risk HPV types 6 and 11. The patient reported a history of multiple sexual partners, did not use condoms during sexual intercourse, and had limited knowledge regarding STIs transmission based on a questionnaire. The patient was treated with cryotherapy and lesion excision. At the final observation, complete lesion resolution was achieved with no new lesions observed. In conclusion, this case highlights the importance of maintaining clinical awareness of AGWs in older adults. Thorough diagnostic evaluation, sexual health education, regular STIs screening, and counseling should be integrated into routine care for the elderly population.
- Open Access
- 24 October 2026
- Published by Wiley in Skin Research and Technology
- Vol. 32 (10)
Clinical and Diagnostic Insights into Penile Angiolymphoid Hyperplasia with Eosinophilia Based on a Case and Analysis of Previous Literature
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign vascular proliferation of unknown origin. It typically occurs in the head and neck region, but can occasionally manifest in unusual locations, such as the penis. Herein, we report a case of ALHE in a 46‐year‐old HIV‐infected male presenting with multiple pruritic whitish nodules on the penile shaft with a size ranging from 0.5 × 0.5 × 0.1 cm to 1.1 × 0.6 × 0.2 cm, initially suspected to be nodular condyloma lata. However, negative serological syphilis test results excluded this initial diagnosis. Histopathological findings were consistent with ALHE, revealing plump endothelial cells and inflammatory infiltrates consisting of lymphocytes and eosinophils. The lesions did not fully resolve with topical corticosteroid therapy, thus necessitating surgical excision. As with ALHE at other sites, recurrence is to be anticipated. Although the pathogenesis remains unclear, an association between ALHE and HIV has been reported. ALHE presents both diagnostic and therapeutic challenges, particularly when it occurs in sensitive areas, such as the penis. While the penis is an atypical site for ALHE, awareness of this disease is important for dermatologists, and it should be included in the differential diagnosis of a penile nodule.
- 24 October 2026
- Published by Wiley in Skin Research and Technology
- Vol. 32 (10)
Open AccessClinical and Diagnostic Insights into Penile Angiolymphoid Hyperplasia with Eosinophilia Based on a Case and Analysis of Previous Literature
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign vascular proliferation of unknown origin. It typically occurs in the head and neck region, but can occasionally manifest in unusual locations, such as the penis. Herein, we report a case of ALHE in a 46‐year‐old HIV‐infected male presenting with multiple pruritic whitish nodules on the penile shaft with a size ranging from 0.5 × 0.5 × 0.1 cm to 1.1 × 0.6 × 0.2 cm, initially suspected to be nodular condyloma lata. However, negative serological syphilis test results excluded this initial diagnosis. Histopathological findings were consistent with ALHE, revealing plump endothelial cells and inflammatory infiltrates consisting of lymphocytes and eosinophils. The lesions did not fully resolve with topical corticosteroid therapy, thus necessitating surgical excision. As with ALHE at other sites, recurrence is to be anticipated. Although the pathogenesis remains unclear, an association between ALHE and HIV has been reported. ALHE presents both diagnostic and therapeutic challenges, particularly when it occurs in sensitive areas, such as the penis. While the penis is an atypical site for ALHE, awareness of this disease is important for dermatologists, and it should be included in the differential diagnosis of a penile nodule.
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-7
A Diagnostic Challenge of A Two-Year Misdiagnosis of Erythema Induratum of Bazin As Erythema Nodosum
Erythema induratum of Bazin (EIB) is an uncommon form of cutaneous tuberculosis (TB) associated with hypersensitivity to Mycobacterium tuberculosis (M. tb). EIB, a type of tuberculid, is characterized by recurrent sore nodules on the lower extremities, which can mimic other dermatologic disorders, such as erythema nodosum (EN), and may result in misdiagnosis and delayed treatment. The aim of this case report was to raise awareness of the diagnostic problem of EIB and the need for thorough diagnostic tools. We present a case of EIB in a 31-year-old woman who was misdiagnosed as EN for two years. On examination, she had several uncomfortable nodules on the distal anterior aspects of both lower legs and the dorsum of the right foot, some ulcerated and healing with hyperpigmentation. The tuberculin test was positive and histopathology showed lobular panniculitis with granulomatous inflammation, Langhans giant cells, epithelioid cells and caseous necrosis. Polymerase chain reaction testing revealed the presence of M. tb deoxyribonucleic acid. In addition, the sputum smear was positive for M. tb and the chest X-ray findings were consistent with pulmonary TB. The woman was diagnosed with EIB with pulmonary TB and her skin lesions improved significantly after two months of anti-tuberculosis treatment. This case highlights the importance of reconsidering the diagnosis of EN in patients with recurrent or ulcerating nodules despite treatment, particularly in TB-endemic settings, and emphasizes the role of histopathological evaluation in diagnosing EIB.
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-7
Open AccessA Diagnostic Challenge of A Two-Year Misdiagnosis of Erythema Induratum of Bazin As Erythema Nodosum
Erythema induratum of Bazin (EIB) is an uncommon form of cutaneous tuberculosis (TB) associated with hypersensitivity to Mycobacterium tuberculosis (M. tb). EIB, a type of tuberculid, is characterized by recurrent sore nodules on the lower extremities, which can mimic other dermatologic disorders, such as erythema nodosum (EN), and may result in misdiagnosis and delayed treatment. The aim of this case report was to raise awareness of the diagnostic problem of EIB and the need for thorough diagnostic tools. We present a case of EIB in a 31-year-old woman who was misdiagnosed as EN for two years. On examination, she had several uncomfortable nodules on the distal anterior aspects of both lower legs and the dorsum of the right foot, some ulcerated and healing with hyperpigmentation. The tuberculin test was positive and histopathology showed lobular panniculitis with granulomatous inflammation, Langhans giant cells, epithelioid cells and caseous necrosis. Polymerase chain reaction testing revealed the presence of M. tb deoxyribonucleic acid. In addition, the sputum smear was positive for M. tb and the chest X-ray findings were consistent with pulmonary TB. The woman was diagnosed with EIB with pulmonary TB and her skin lesions improved significantly after two months of anti-tuberculosis treatment. This case highlights the importance of reconsidering the diagnosis of EN in patients with recurrent or ulcerating nodules despite treatment, particularly in TB-endemic settings, and emphasizes the role of histopathological evaluation in diagnosing EIB.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-15
Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents
Prurigo nodularis (PN) is a chronic inflammatory disease characterized by hyperkeratotic nodules on extensor surfaces, perpetuating a vicious itch-scratch cycle. Its epidemiologic burden is substantial, and diagnosis remains primarily clinical, supported by a structured diagnostic algorithm and evaluation for associated comorbidities. PN pathogenesis involves interactions among keratinocytes, immune cells, sensory nerve fibers and neuropeptides (substance P and calcitonin gene-related peptide) that elicit intense pruritus. Therapy aims to break the itch-scratch cycle and accelerate lesion resolution by reducing pruritus. Standard management with topical agents (corticosteroids, calcineurin inhibitors), systemic therapies (antihistamines, methotrexate, cyclosporine) and phototherapy often yields incomplete responses and requires prolonged treatment. Consequently, targeted therapies are critical to optimizing clinical efficacy. Dupilumab is currently the first Food and Drug Administration (FDA)-approved biologic for PN, followed by nemolizumab whereas other emerging agents—including additional monoclonal antibodies, Janus kinase (JAK) inhibitors, neurokinin-1 (NK1) receptor antagonists, opioid antagonists, and neuromodulators—remain at varying stages of clinical investigation (Phase II–III), acting on cytokine–neuroinflammatory pathways to relieve pruritus and improve patients’ quality of life.
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-15
Open AccessLiterature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents
Prurigo nodularis (PN) is a chronic inflammatory disease characterized by hyperkeratotic nodules on extensor surfaces, perpetuating a vicious itch-scratch cycle. Its epidemiologic burden is substantial, and diagnosis remains primarily clinical, supported by a structured diagnostic algorithm and evaluation for associated comorbidities. PN pathogenesis involves interactions among keratinocytes, immune cells, sensory nerve fibers and neuropeptides (substance P and calcitonin gene-related peptide) that elicit intense pruritus. Therapy aims to break the itch-scratch cycle and accelerate lesion resolution by reducing pruritus. Standard management with topical agents (corticosteroids, calcineurin inhibitors), systemic therapies (antihistamines, methotrexate, cyclosporine) and phototherapy often yields incomplete responses and requires prolonged treatment. Consequently, targeted therapies are critical to optimizing clinical efficacy. Dupilumab is currently the first Food and Drug Administration (FDA)-approved biologic for PN, followed by nemolizumab whereas other emerging agents—including additional monoclonal antibodies, Janus kinase (JAK) inhibitors, neurokinin-1 (NK1) receptor antagonists, opioid antagonists, and neuromodulators—remain at varying stages of clinical investigation (Phase II–III), acting on cytokine–neuroinflammatory pathways to relieve pruritus and improve patients’ quality of life.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Rapidly Progressive Perianal Giant Condyloma in an Immunocompetent Adolescent: An Unusual Abuse-Associated Case
Buschke–Löwenstein tumor (BLT) is a rare, locally aggressive variant of condyloma acuminata associated predominantly with HPV genotypes 6 and 11. It presents as a progressively enlarging, exophytic, verrucous mass in the anogenital region with infiltrative growth and potential for significant local destruction. Predisposing factors include diabetes mellitus, tobacco and alcohol use, pregnancy, chemotherapy, and immunosuppression; however, cases in immunocompetent individuals have been reported. A 15-year-old female presented with an 8.5 cm perianal verrucous mass. She had no comorbidities or conventional risk factors but reported sexual assault 1.5 years earlier. Histopathology confirmed giant condyloma acuminata, and PCR genotyping identified HPV type 11. Laboratory findings, including HIV serology, were unremarkable. Complete surgical excision was performed without complications. At the one-month follow-up after the excision procedure, all lesions had disappeared, and no new lesions had appeared. This case highlights the unusual occurrence of BLT in an immunocompetent adolescent after sexual assault and emphasizes the importance of early recognition, consideration of underlying abuse, and timely management to prevent disease progression.
- 1 May 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Open AccessRapidly Progressive Perianal Giant Condyloma in an Immunocompetent Adolescent: An Unusual Abuse-Associated Case
Buschke–Löwenstein tumor (BLT) is a rare, locally aggressive variant of condyloma acuminata associated predominantly with HPV genotypes 6 and 11. It presents as a progressively enlarging, exophytic, verrucous mass in the anogenital region with infiltrative growth and potential for significant local destruction. Predisposing factors include diabetes mellitus, tobacco and alcohol use, pregnancy, chemotherapy, and immunosuppression; however, cases in immunocompetent individuals have been reported. A 15-year-old female presented with an 8.5 cm perianal verrucous mass. She had no comorbidities or conventional risk factors but reported sexual assault 1.5 years earlier. Histopathology confirmed giant condyloma acuminata, and PCR genotyping identified HPV type 11. Laboratory findings, including HIV serology, were unremarkable. Complete surgical excision was performed without complications. At the one-month follow-up after the excision procedure, all lesions had disappeared, and no new lesions had appeared. This case highlights the unusual occurrence of BLT in an immunocompetent adolescent after sexual assault and emphasizes the importance of early recognition, consideration of underlying abuse, and timely management to prevent disease progression.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-8
Unusual Presentation of Syphilis a Case Report: Areolar Condyloma Lata in a Patient with Human Immunodeficiency Virus Infection
Syphilis is a sexually transmitted infection caused by Treponema pallidum, primarily transmitted by sexual intercourse. Secondary syphilis is characterized by lesions on the skin and mucosal membranes, including condyloma lata (CL), occurring in 17% of secondary syphilis cases. Papules or flat-colored skin plaques are characteristic of CL. They are typically found in humid regions, such as skin folds, including the labia majora, perianal area, axilla, interdigital spaces, and inframammary folds. Presentation in an open region of the body, such as the nipple and the surrounding area of the breast, is rare. Herein we report a case of a 30-year-old female presenting with papules on both breasts and roseola syphilitica with Biett’s collarette on both palms and soles that had not been pruritic nor painful for three weeks. The patient has been treated for human immunodeficiency virus (HIV) for the past year. The patient was involved in prostitution for three years, with a total of 6 sexual partners. T. pallidum Hemagglutination Assay (TPHA) and the Venereal Disease Research Laboratory (VDRL) were reactive, with a VDRL titer of 1:8. The patient received a single dose of benzathine penicillin 2.4 million IU injected intramuscularly. The histopathology examination from papules on the breast confirmed the diagnosis of CL, which revealed lymphoplasmacytic infiltrates around the blood vessels and plump endothelial cells. The skin-colored papules on both areolas and the rash associated with secondary syphilis on both palms and soles began to fade two weeks after the intramuscular injection of single dose benzathine penicillin 2.4 million IU. Unusual presentation of secondary syphilis outside predilection sites is possible. A high degree of suspicion is warranted when unusual papules are present, especially with a background of multiple sexually transmitted diseases and immunocompromised condition.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-8
Open AccessUnusual Presentation of Syphilis a Case Report: Areolar Condyloma Lata in a Patient with Human Immunodeficiency Virus Infection
Syphilis is a sexually transmitted infection caused by Treponema pallidum, primarily transmitted by sexual intercourse. Secondary syphilis is characterized by lesions on the skin and mucosal membranes, including condyloma lata (CL), occurring in 17% of secondary syphilis cases. Papules or flat-colored skin plaques are characteristic of CL. They are typically found in humid regions, such as skin folds, including the labia majora, perianal area, axilla, interdigital spaces, and inframammary folds. Presentation in an open region of the body, such as the nipple and the surrounding area of the breast, is rare. Herein we report a case of a 30-year-old female presenting with papules on both breasts and roseola syphilitica with Biett’s collarette on both palms and soles that had not been pruritic nor painful for three weeks. The patient has been treated for human immunodeficiency virus (HIV) for the past year. The patient was involved in prostitution for three years, with a total of 6 sexual partners. T. pallidum Hemagglutination Assay (TPHA) and the Venereal Disease Research Laboratory (VDRL) were reactive, with a VDRL titer of 1:8. The patient received a single dose of benzathine penicillin 2.4 million IU injected intramuscularly. The histopathology examination from papules on the breast confirmed the diagnosis of CL, which revealed lymphoplasmacytic infiltrates around the blood vessels and plump endothelial cells. The skin-colored papules on both areolas and the rash associated with secondary syphilis on both palms and soles began to fade two weeks after the intramuscular injection of single dose benzathine penicillin 2.4 million IU. Unusual presentation of secondary syphilis outside predilection sites is possible. A high degree of suspicion is warranted when unusual papules are present, especially with a background of multiple sexually transmitted diseases and immunocompromised condition.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 6727-6736
Otosyphilis and Malignant Syphilis in a Human Immunodeficiency Virus–Infected Patient: A Case of Bilateral Hearing Loss with Complete Recovery Following Ceftriaxone Therapy – Case Report
Syphilis is characterized by diverse manifestations, including rare complications such as otosyphilis and malignant syphilis, particularly in immunocompromised individuals. This study reported a case of a 40-year-old Human Immunodeficiency Virus (HIV)-positive male with bilateral sensorineural hearing loss (SNHL) and disseminated ulceronodular skin lesions. Serological testing confirmed active Treponema pallidum infection with a venereal disease research laboratory (VDRL) titer of 1:64. Dermatological results were consistent with malignant syphilis, a rare and aggressive variant of secondary syphilis. Audiological assessment showed mild bilateral SNHL, while cerebrospinal fluid analysis was insignificant. Although histopathological confirmation was not performed due to rapid clinical improvement, a presumptive diagnosis of otosyphilis was made. The patient was treated with intramuscular ceftriaxone 2 grams daily for 14 days as an alternative to penicillin due to accessibility constraints and preference. This led to complete resolution of hearing loss, regression of cutaneous lesions, and a significant clinical serological response, including VDRL seroconversion at 6 months. The treatment did not produce Jarisch–Herxheimer reaction, showing good tolerance and supporting ceftriaxone effectiveness as an alternative therapy in HIV-associated syphilis. This case study underscores the importance of early recognition and treatment of otosyphilis and malignant syphilis in HIV-infected individuals. Ceftriaxone may serve as an effective alternative regimen to penicillin, achieving both clinical and serological recovery. Moreover, routine screening for otologic symptoms in patient with syphilis is critical to prevent irreversible complications. The limitations include the absence of histopathology and CSF analysis conducted after therapy initiation.
- 1 December 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 6727-6736
Open AccessOtosyphilis and Malignant Syphilis in a Human Immunodeficiency Virus–Infected Patient: A Case of Bilateral Hearing Loss with Complete Recovery Following Ceftriaxone Therapy – Case Report
Syphilis is characterized by diverse manifestations, including rare complications such as otosyphilis and malignant syphilis, particularly in immunocompromised individuals. This study reported a case of a 40-year-old Human Immunodeficiency Virus (HIV)-positive male with bilateral sensorineural hearing loss (SNHL) and disseminated ulceronodular skin lesions. Serological testing confirmed active Treponema pallidum infection with a venereal disease research laboratory (VDRL) titer of 1:64. Dermatological results were consistent with malignant syphilis, a rare and aggressive variant of secondary syphilis. Audiological assessment showed mild bilateral SNHL, while cerebrospinal fluid analysis was insignificant. Although histopathological confirmation was not performed due to rapid clinical improvement, a presumptive diagnosis of otosyphilis was made. The patient was treated with intramuscular ceftriaxone 2 grams daily for 14 days as an alternative to penicillin due to accessibility constraints and preference. This led to complete resolution of hearing loss, regression of cutaneous lesions, and a significant clinical serological response, including VDRL seroconversion at 6 months. The treatment did not produce Jarisch–Herxheimer reaction, showing good tolerance and supporting ceftriaxone effectiveness as an alternative therapy in HIV-associated syphilis. This case study underscores the importance of early recognition and treatment of otosyphilis and malignant syphilis in HIV-infected individuals. Ceftriaxone may serve as an effective alternative regimen to penicillin, achieving both clinical and serological recovery. Moreover, routine screening for otologic symptoms in patient with syphilis is critical to prevent irreversible complications. The limitations include the absence of histopathology and CSF analysis conducted after therapy initiation.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 17, 399-406
Clinical Experience and Pitfalls in Using Glycyrrhizic Acid for Treating Anogenital Warts in an HIV-Infected Patient in Indonesia: A Case Report
Anogenital warts (AGW) are a common manifestation of human papillomavirus (HPV) infection, primarily caused by strains 6 and 11. According to results, mucosal HPV is transmitted through sexual contact, with risk factors including immunodeficiency, such as Human Immunodeficiency Virus (HIV). Individuals with HIV experience a higher incidence of AGW due to impaired immune function that hinders HPV clearance. There is currently no specific antiviral therapy available for HPV, although several management options exist. However, some of these treatments may cause pain and discomfort. Glycyrrhizinic acid (GA) has demonstrated potential in managing HPV infection because of its antiviral properties and minimal side effects. Despite these promising results, GA is not yet recognized as a standard therapy for AGW. This case report describes the effectiveness of Glizigen® (topical GA) combined with Viusid® (oral GA) in managing genital warts in a 28-year-old homosexual male living with HIV. The patient, examined by a dermatologist at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, presented with perianal warts that had developed over 3 months. According to the physical examination carried out, multiple flesh-colored papules were reported, while histopathological analysis showed koilocytes, and polymerase chain reaction (PCR) confirmed HPV types 6 and 11. The treatment process, carried out using topical and oral GA, was administered from August to October 2024. The improvement was reported only in smaller lesions, while larger ones persisted, leading to electrocautery scheduling. The limited response observed in this case might be influenced by the patient’s low CD4+ count, which potentially affects HPV clearance. Factors such as age, number of sexual partners, circumcision status, HPV type, and anatomical location of the lesions may also have played a role.
- 1 December 2025
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 17, 399-406
Open AccessClinical Experience and Pitfalls in Using Glycyrrhizic Acid for Treating Anogenital Warts in an HIV-Infected Patient in Indonesia: A Case Report
Anogenital warts (AGW) are a common manifestation of human papillomavirus (HPV) infection, primarily caused by strains 6 and 11. According to results, mucosal HPV is transmitted through sexual contact, with risk factors including immunodeficiency, such as Human Immunodeficiency Virus (HIV). Individuals with HIV experience a higher incidence of AGW due to impaired immune function that hinders HPV clearance. There is currently no specific antiviral therapy available for HPV, although several management options exist. However, some of these treatments may cause pain and discomfort. Glycyrrhizinic acid (GA) has demonstrated potential in managing HPV infection because of its antiviral properties and minimal side effects. Despite these promising results, GA is not yet recognized as a standard therapy for AGW. This case report describes the effectiveness of Glizigen® (topical GA) combined with Viusid® (oral GA) in managing genital warts in a 28-year-old homosexual male living with HIV. The patient, examined by a dermatologist at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, presented with perianal warts that had developed over 3 months. According to the physical examination carried out, multiple flesh-colored papules were reported, while histopathological analysis showed koilocytes, and polymerase chain reaction (PCR) confirmed HPV types 6 and 11. The treatment process, carried out using topical and oral GA, was administered from August to October 2024. The improvement was reported only in smaller lesions, while larger ones persisted, leading to electrocautery scheduling. The limited response observed in this case might be influenced by the patient’s low CD4+ count, which potentially affects HPV clearance. Factors such as age, number of sexual partners, circumcision status, HPV type, and anatomical location of the lesions may also have played a role.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1473-1481
Intralesional Vitamin D3 for Anogenital Warts in Human Immunodeficiency Virus Infected Individual
Anogenital warts (AGW) is the most common sexually transmitted infection in the world caused by the Human Papillomavirus (HPV), especially types 6 and 11. Immunotherapy is one of the therapeutic modalities that can be used to treat AGW. The mechanism of Vitamin D3 on AGW is the expression of antimicrobial peptides (AMP) that directly inactivate pathogens and also enhance innate immune responses. One case of AGW type condyloma acuminata was reported in a 29-year-old male. A case of condyloma acuminata-type AGW in a 29-year-old HIV stage 1 male patient was reported. His CD4 level was 500 cells/uL, and treated with anti-retroviral (ARV). Physical examination of the perianal area revealed a skin-colored tumor with a verrucous surface. Acetowhite test and HPV type 11 polymerase chain reaction (PCR) results were positive. The patient received intralesional injection of vitamin D3 60,000 IU per lesion every two weeks four times. The lesions appeared to have shrunk by more than 50% after the fourth injection. This case report shows the potential of intralesional vitamin D3 for the treatment of AGWs in an HIV patient. However, further research is required to confirm both the efficacy and safety of intralesional vitamin D3.
- 1 November 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1473-1481
Open AccessIntralesional Vitamin D3 for Anogenital Warts in Human Immunodeficiency Virus Infected Individual
Anogenital warts (AGW) is the most common sexually transmitted infection in the world caused by the Human Papillomavirus (HPV), especially types 6 and 11. Immunotherapy is one of the therapeutic modalities that can be used to treat AGW. The mechanism of Vitamin D3 on AGW is the expression of antimicrobial peptides (AMP) that directly inactivate pathogens and also enhance innate immune responses. One case of AGW type condyloma acuminata was reported in a 29-year-old male. A case of condyloma acuminata-type AGW in a 29-year-old HIV stage 1 male patient was reported. His CD4 level was 500 cells/uL, and treated with anti-retroviral (ARV). Physical examination of the perianal area revealed a skin-colored tumor with a verrucous surface. Acetowhite test and HPV type 11 polymerase chain reaction (PCR) results were positive. The patient received intralesional injection of vitamin D3 60,000 IU per lesion every two weeks four times. The lesions appeared to have shrunk by more than 50% after the fourth injection. This case report shows the potential of intralesional vitamin D3 for the treatment of AGWs in an HIV patient. However, further research is required to confirm both the efficacy and safety of intralesional vitamin D3.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 2119-2125
Complete Regression of Anogenital Warts Following Intralesional Measles-Mumps-Rubella (MMR) Vaccine: A Case of Two
Introduction: Anogenital warts (AGW) are benign proliferative lesions on the epithelium or mucosa caused by human papillomavirus (HPV) types 6 and 11. HPV infection occurs when viral particles enter the basal cells through microtrauma in the epithelium. AGW demonstrate a predilection for involvement of any region of the genitalia, anal or perianal area, inguinal, pubic region, and is very common in the traumatized area during sexual intercourse. Immunotherapy is one of the therapeutic modalities for AGW. The measles, mumps, and rubella (MMR) vaccine given by intralesional injection can be a promising therapeutic option for multiple AGW, particularly those located hard to reach areas. Case Presentation: We described two cases of anogenital wart type condyloma acuminata in a 19-year-old female and 21-year old female patient, who presented to Dermatology, Venereology, and Aesthetic Department. On physical examination, both cases have multiple skin-colored papules appeared with a verrucous surface in the labia majora and vagina. The patients received 0.5 mL of MMR vaccine, which was injected intralesional into the largest wart without a pre-sensitization test. The injections are planned to be administered every three weeks, with a maximum of three injections. The warts resolved completely and left no scars. The side effect when the injection is mild pain in the injection site. Conclusion: Intralesional MMR vaccine can be considered one of the treatments for AGW because it has been proven safe and effective, but more research is needed as a therapy for AGW.
- 1 September 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 2119-2125
Open AccessComplete Regression of Anogenital Warts Following Intralesional Measles-Mumps-Rubella (MMR) Vaccine: A Case of Two
Introduction: Anogenital warts (AGW) are benign proliferative lesions on the epithelium or mucosa caused by human papillomavirus (HPV) types 6 and 11. HPV infection occurs when viral particles enter the basal cells through microtrauma in the epithelium. AGW demonstrate a predilection for involvement of any region of the genitalia, anal or perianal area, inguinal, pubic region, and is very common in the traumatized area during sexual intercourse. Immunotherapy is one of the therapeutic modalities for AGW. The measles, mumps, and rubella (MMR) vaccine given by intralesional injection can be a promising therapeutic option for multiple AGW, particularly those located hard to reach areas. Case Presentation: We described two cases of anogenital wart type condyloma acuminata in a 19-year-old female and 21-year old female patient, who presented to Dermatology, Venereology, and Aesthetic Department. On physical examination, both cases have multiple skin-colored papules appeared with a verrucous surface in the labia majora and vagina. The patients received 0.5 mL of MMR vaccine, which was injected intralesional into the largest wart without a pre-sensitization test. The injections are planned to be administered every three weeks, with a maximum of three injections. The warts resolved completely and left no scars. The side effect when the injection is mild pain in the injection site. Conclusion: Intralesional MMR vaccine can be considered one of the treatments for AGW because it has been proven safe and effective, but more research is needed as a therapy for AGW.